REG - SkinBioTherapeutics - Warrant Exercise Notice and Total Voting Rights

SkinbiotherapeuticsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250428:nRSb3412Ga&default-theme=true

RNS Number : 3412G  SkinBioTherapeutics PLC  28 April 2025

28 April 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

 

Warrant Exercise Notice and Total Voting Rights

 

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science
business focused on skin health, announces that it received an Exercise Notice
from Macquarie ("Macquarie") for 1,099,244 ordinary shares in
SkinBioTherapeutics plc at £0.2043 per share.

 

Following the above exercise, no outstanding warrants remain with Macquarie.

 

Admission and Total Voting Rights

 

Application has been made for the 1,099,244 new ordinary shares, which will
rank pari passu in all respects with the existing ordinary shares of the
Company, to be admitted to AIM, which is expected to occur on or around 8.00
a.m. on 1 May 2025 ("Admission"). Upon Admission, the total number of issued
shares and the total number of voting rights in the Company will be
234,074,627.

 

The above figure of 234,074,627 should be used by shareholders in the Company
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in,
the share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

 

-Ends-

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

For more information please contact:

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Martin Hunt, Chair

 Stuart J. Ashman, CEO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements to modulate the immune system by harnessing the gut-skin
axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and
the SkinBiotix active ingredient, Zenakine™ was launched in April 2025. The
Group's first in-house product, AxisBiotix-Ps™, is a food supplement to
address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBLGDSBUDDGUR